Co.'s samRNA Vaccines Protect Better Against COVID Variants
January 10, 2022 (Investorideas.com Newswire) Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio.
In a Jan. 4 research note, BTIG Research Analyst Kaveri Pohlman, Ph.D. advised that key readout data from Gritstone bio Inc.'s (GRTS:NASDAQ) low-dose vaccine demonstrated "robust T-cell responses against non-Spike proteins/T-cell epitopes." Dr. Pohlman commented that these T-cell responses highlight Gritstone bio's value proposition.
For comparison and verification purposes, the analyst stated that results were reassuring as Gritstone's vaccine measured neutralizing antibody responses against the WT (pseudovirus neutralizing NT50 titers) were similar for the samRNA at a reading of 2,370 compared to 2,368 for Moderna Inc.'s (MRNA:NASDAQ) mRNA vaccine and for the delta variant Gritstone's registered 525 versus 580 for MRNA.
The analyst pointed out that the equivalent antibody responses were achieved at a lower total mRNA level (10μg dose, n = 10) than the Moderna offering which suggests that the "sam" technology is effective.
The BTIG report stated that though the impressive CD8+ response observed with Gritstone's vaccine has not yet been fully validated in clinical trials, important United Kingdom epidemiological data collected indicates that "T-cell responses against non-spike proteins might provide better protection against all the variants of coronavirus."
The company is now planning to increase the number of participants in its P1 study to 120 patients. The enrollees will be split into two cohorts that will be given either 10μg or 30μg doses to evaluate the addition of a second samRNA vaccine. The study will also evaluate samRNA's potential as a booster vaccine.
The BTIG report stated that the recent surge in Omicron serves as a signal that additional SARS-CoV-2 variants may follow and that first-generation vaccines that were developed in the fight against the original WT Wuhan strain may be ineffective.
The analyst remarked that in order to move away from vaccines that principally target surface regions with antibody-focused immunity, Gritstone is exploring pathways to broader spectrum vaccines that also generate T-cell responses. As an example, the report from BTIG noted that, "Gritstone's broadly-immunizing beta variant vaccine has shown cross-reactivity against delta and WT strains pre-clinically, while previous delta and WT vaccines don't neutralize beta variant."
BTIG stated that it currently has a "Buy" rating for Gritstone bio Inc. with a price target of $20.00/share. Gritstone bio's shares trade on the Nasdaq Exchange in the United States under the symbol "GRTS" and last closed for trading at $6.73 on Thursday, Jan. 6, 2022.
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures for BTIG LLC, Gritstone bio Inc., Jan. 4, 2022
Analyst Certification: I, Kaveri Pohlman, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.
Regulatory Disclosures: Company Valuation and Risk Disclosures: Gritstone bio (GRTS, Buy, $20 PT). Valuation: We value Gritstone using a discounted cash flow analysis that assumes a 19% discount rate and 1% terminal growth rate. Risks: Risks include expected risk of drug development and the risks associated with genomics-based medicine.
Company-Specific Regulatory Disclosures: BTIG LLC expects to receive or intends to seek compensation for investment banking services in the next 3 months from: Gritstone bio (GRTS).
Other Disclosures: Additional Information Available Upon Request.
General Disclosures: Research reports produced by BTIG LLC ("BTIG") are published for and intended to be distributed solely to BTIG institutional and corporate clients. Recipients of BTIG reports will not be considered clients of BTIG solely because they may have received such BTIG report. To the extent recipient accesses BTIG research, whether on a BTIG research website or through a third-party platform, BTIG is able to search, filter, download and review information on the readership of BTIG's research, including the specific research consumed and the name, company name, email address and, in certain circumstances, the location of the individual who accessed the research (the "Readership Information"). Recipient consents to BTIG's receipt of the Readership Information, including receipt of that information from a third party.
The research analyst(s) responsible for the preparation of this report receives compensation based upon a variety of factors, including the quality and accuracy of research, internal/client feedback, and overall Firm revenues.
BTIG reports are based on public information and BTIG considers the same to be reliable, comprehensive information, but makes no representation or warranty that the reports are accurate or complete. BTIG opinions and information provided in this report are as of the date of the report and may change without notice. An issuer may be classified as "Under Review" or "Research Restricted". In these cases, investors should consider any previous investment recommendation and/or rating to a subject company/issuer to no longer be current and should not be relied upon nor considered a solicitation.
This research report is not an offer to buy or sell or solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal. This research report was not drafted specifically for any particular individual or entity and is not a personal recommendation to participate in any particular trading strategy or transaction. Any recipient of this research report should obtain independent advice specific to their personal circumstances before undertaking any investment activity and must make their own independent evaluation of any securities or financial instruments.
Facts, views or opinions presented in this report have not been reviewed by, and may not reflect information known to, employees or other professionals in the "BTIG Group" (BTIG Group includes, but is not limited to, BTIG and its parents, subsidiaries and/ or affiliates). BTIG Group employees, including Sales Representatives and Traders, may provide oral or written commentary or advice that may be inconsistent with the opinions and/or views expressed in this research report. BTIG Group employees and/or its affiliates not involved in the preparation of this research report may have investments in securities or derivatives of securities of companies mentioned in this report that are inconsistent with the views discussed in this report.
Investors in securities products bear certain risks in conjunction with those investments. The value of, and income from, any investments may vary because of changes in interest rates or foreign exchange rates, securities prices or market indexes, operational or financial conditions of companies or other factors within or beyond the companies' control. Recipient of the research reports should be aware that investments in securities may pose significant risks due to the inherent uncertainty associated with relying on forecasts of various factors that can affect the earnings, cash flow and overall valuation of a company. Any investment in securities should be undertaken only upon consideration of issues relating to the recipient's overall investment portfolio and objectives (such as diversification by asset class, industry or company) as well as time horizon and liquidity needs. Further, past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. There may be time limitations on the exercise of options or other rights in any securities transactions.
Investing in foreign markets and securities, including ADRs, is subject to additional risks such as currency fluctuation, limited information, political instability, economic risk, and the potential for illiquid markets. Investing in emerging markets may accentuate these risks. Non-U.S. reporting issuers of foreign securities, however, may not make regular or complete public disclosure relating to their financial condition or the securities that they issue.
The trademarks and service marks contained herein are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability of any damages of any kind relating to such data. The report or any portion hereof may not be reprinted, sold or redistributed without the written consent of BTIG. This report is intended only for use by the recipient. The recipient acknowledges that all research and analysis in this report are the property of BTIG and agrees to limit the use of all publications received from BTIG within his, or her or its, own company or organization. No rights are given for passing on, transmitting, re transmitting or reselling the information provided.
Jurisdiction and Dissemination: BTIG is a U.S. broker-dealer and member of FINRA and SIPC. BTIG Australia Limited ACN 128 554 601, member of ASIC and ASX; BTIG Hong Kong Limited, an Exchange Participant of SEHK and licensed and regulated by the SFC; BTIG Ltd, member of the LSE, authorized and regulated by the FSA; and BTIG Singapore Pte Ltd, registered and licensed with MAS; are all separate but affiliated entities of BTIG. Unless governing law permits otherwise, you must contact a BTIG entity in your home jurisdiction for further information, or if you want to use our services in effecting a transaction.
Issued and approved for distribution in the UK and EEA by BTIG Ltd. to eligible counterparties and professional clients only. Issued and distributed in Australia to "wholesale clients" only by BTIG Australia Limited. In Singapore and Hong Kong, further information may be obtained from BTIG Singapore Pte Ltd and BTIG Hong Kong Limited, respectively.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com